Page 18 - Diagnostics Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from Avacta Group PLC, MHRA Confirms Registration of Lateral Flow Test

    Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that its Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the 2021 Annual General Meeting are now available on the Company's website, www.avacta.com. Copies of the Annual Report and Accounts and the Notice of AGM have been posted to shareholders who have elected to receive them in paper form.   The Annual General Meeting will be held on...

Investegate announcements from Avacta Group PLC, Change of Nominated Adviser

Investegate announcements from Avacta Group PLC, Issue of Equity

Commenting on the Group’s performance in the first quarter, Roche CEO Severin Schwan said: “In 2021, Roche remains strongly committed to the fight against COVID-19. The uptake of our recently introduced diagnostic tests and medicines remains strong, while we continue to see the expected impact from biosimilars on sales of our established medicines. Our broad product pipeline keeps making good progress. I am particularly pleased about the highly encouraging study results of our immunotherapy Tecentriq in early lung cancer and of faricimab in ophthalmology. The upcoming acquisition ...